Can-Fite BioPharma (CANF) Announces Submission of CF102 Phase 2 Protocol as NAFLD/NASH Treatment
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Can-Fite BioPharma Ltd. (NYSE: CANF) announced it has submitted the clinical trial protocol for its Phase II study of CF102 in the treatment of non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH), to a leading Institutional Review Board (IRB) in Israel. Top medical centers in Israel, including Hadassah Medical Center and Rabin Medical Center are expected to participate in the planned study by enrolling and treating patients.
"We are eager to commence our Phase II study in NAFLD/NASH, an indication for which there is no U.S. FDA approved drug. We view the submission of our clinical trial protocol as a major step forward," stated Can-Fite CEO Dr. Pnina Fishman.
Based on the protocol that was submitted, Can-Fite's Phase II study, designed by world renowned Key Opinion Leaders in the field of liver diseases, will be a multicenter, randomized, double-blinded, placebo-controlled, dose-finding study of the efficacy and safety of CF102 in the treatment of NAFLD/NASH. The study will enroll approximately 60 patients with NAFLD, with or without NASH, and will have three arms, including two different dosages of CF102 and a placebo, given via oral tablets twice daily. The study's primary endpoints will be percent change from baseline in liver triglyceride (fat) concentration measured by nuclear magnetic resonance spectroscopy (NMRS) and safety. Secondary endpoints to be evaluated are the effects of CF102 on metabolic abnormalities in subjects with NAFLD, including body weight, waist circumference, serum triglyceride and high-density lipoprotein cholesterol levels, and serum liver transaminase. In addition, an assessment of the pharmacokinetics (PK) of CF102 and the A3 adenosine receptor (A3AR) biomarker will be evaluated prior to treatment and its correlation to patients' response to the drug will be analyzed upon study conclusion. Furthermore, the exploratory objective of this study is to evaluate the effects of CF102 on relevant biomarkers, such as adiponectin, leptin, C-reactive protein (CRP), and liver stiffness as determined by Fibroscan. The trial design is based on preclinical studies showing CF102's efficacy in reducing liver fat in NASH models as compared to placebo, improving liver function, and regenerating liver cells.
Deutsche Bank estimates the addressable pharmaceutical market for NASH will reach $35-40 billion in size by 2025.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ladder Capital (LADR) Prices 10M Share Secondary Stock Offering for Proceeds of ~$136M
- Merck (MRK) Announces Positive HRQoL Data from KEYTRUDA Phase 3 KEYNOTE-024 Study
- Omeros (OMER) Presents Positive Results from OMS721 Phase 2 in HSCT-TMA
Create E-mail Alert Related CategoriesCorporate News, FDA
Related EntitiesDeutsche Bank
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!